Clinical Trial Update: Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma: [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/Phase II study updates for MK-3475 in combination for clear cell renal cell carcinoma have completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• MK-3475 (pembrolizumab)

Snippet

Sponsor: Arkadiusz Z. Dudek, MD | Conditions: Clear Cell Renal Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-07-31